CXCL16



CXCL16

N1NN1Q2QQ2G3GG3S4SS4V5VV5A6AA6G7GG7S8SS8C9CC9Y10YY10C11CC11D12DD12R13RR13T14TT14I15II15P16PP16S17SS17G18GG18T19TT19Q20QQ20I21II21P22PP22P23PP23A24AA24T25TT25L26LL26N27NN27H28HH28M29MM29R30RR30K31KK31Y32YY32L33LL33K34KK34T35TT35F36FF36H37HH37R38RR38C39CC39Q40QQ40F41FF41F42FF42I43II43R44RR44F45FF45Q46QQ46L47LL47... and 174 more residue(s)...... and 174 more residue(s)

SMILES None
InChIKey None
Sequence NQGSVAGSCYCDRTIPSGTQIPPATLNHMRKYLKTFHRCQFFIRFQLQSKSVCGGSQDQWVRELVNCFEHKQCGIGHGQSFHHQKHVPQASTRIPEATEGKPPDTSTAVQFQSTQQSTFPSGAPSLNKELTRHWETTILPSGYGLEARPVAEANEKQHKQQKEPGAGAGTQALVPVLSLLAIVFFLVAAMVCVLCNRRVTRQSSSGLQLCYTPVEPRPQGL

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CXCL16

N1NN1Q2QQ2G3GG3S4SS4V5VV5A6AA6G7GG7S8SS8C9CC9Y10YY10C11CC11D12DD12R13RR13T14TT14I15II15P16PP16S17SS17G18GG18T19TT19Q20QQ20I21II21P22PP22P23PP23A24AA24T25TT25L26LL26N27NN27H28HH28M29MM29R30RR30K31KK31Y32YY32L33LL33K34KK34T35TT35F36FF36H37HH37R38RR38C39CC39Q40QQ40F41FF41F42FF42I43II43R44RR44F45FF45Q46QQ46L47LL47... and 174 more residue(s)...... and 174 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.